 |
Flot.bio x Philip HemmeAuthor: Flot.bio
Watch the best Europeans in biotech to grow. Hosted by Philip Hemme. 10k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, and Sander van Deventer @VectorY & Forbion. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. Language: en-us Genres: Life Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Marina Udier, Nouscom 🇨🇭 | Cancer Vaccines, Neoantigens | E21
Episode 21
Tuesday, 1 October, 2024
We’re in Basel 🇨🇭 with the CEO of Nouscom, one of the top EU immuno-oncology biotechs in the cancer vaccine space, Marina Udier. We talked about cancer vaccines and Nouscom’s platform. We also discussed the importance of focus for success and her career. ⭐️ ABOUT THE SPEAKER Marina was recommended to me by one of her investors. She has an inspiring story, growing up in Croatia, going to the US, and making it all the way to be one of the 11% of female CEOs of biotechs in Europe in 2024. Now she is the CEO of Nouscom, but prior she was the Operating Principal at Versant Ventures, as well as holding top-level positions at Novartis Pharma, and McKinsey & Company. 🔗 LINKS MENTIONED - Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial - ****https://investors.modernatx.com/news/news-details/2022/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-with-KEYTRUDAR-pembrolizumab-Met-Primary-Efficacy-Endpoint-in-Phase-2b-KEYNOTE-942-Trial/default.aspx?os=vb&ref=app - Agnete Fredriksen, Nykode | Being one of the top 50 women in 🇪🇺 bio | E07 - https://flot.bio/episode/agnete-fredriksen-top-women-bio/ - BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024 - https://investors.biontech.de/news-releases/news-release-details/biontech-present-clinical-data-updates-across-mrna-and - Nouscom Raises €67.5 Million ($72 Million) In Oversubscribed Series C Financing Round - https://nouscom.com/2023/11/14/nouscom-raises-e67-5-million-72-million-in-oversubscribed-series-c-financing-round-2-2/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/marina-udier-nouscom-cancer-vaccines/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. [🎙️](https://x.com/FlotBio) ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS - [00:00:00] Intro - [00:02:18] Cancer vaccines & Nouscom - [00:10:39] Bioinformatics algorithm - [00:15:16] Hype cycle in cancer vaccines - [00:26:04] $72M series C - [00:33:35] Managing a biotech board - [00:42:22] Personal story of Marina Udier - [00:48:17] Transition from Novartis - [00:54:00] Luck and timing in biotech - [00:56:10] Headwinds, Tailwinds - [00:58:13] Finding focus with a small team - [01:06:33] Gender diversity in biotech - [01:16:01] Quick fire - [01:18:37] Thanks for listening
